Glucuronidation of edaravone by human liver and kidney microsomes: Biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform

Drug Metabolism and Disposition

Volumn 40, Issue 4, 2012, Pages 734-741

  Ma, Liping ^a   Sun, Jianguo ^a   Peng, Ying ^a   Zhang, Rong ^a   Shao, Feng ^b   Hu, Xiaoling ^b   Zhu, Jianping ^a   Wang, Xiaojin ^a   Cheng, Xuefang ^a   Zhu, Yinci ^a   Wan, Ping ^a   Feng, Dong ^a   Wu, Hui ^a   Wang, Guangji ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b Jiangsu Simcere Pharmaceutical Research Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTERONE; ESTRADIOL; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A7; GLUCURONOSYLTRANSFERASE 1A8; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B17; GLUCURONOSYLTRANSFERASE 2B7; NALOXONE; NORPHENAZONE; PROPOFOL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME KINETICS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY MICROSOME; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR AFFINITY; TANDEM MASS SPECTROMETRY;

ANDROSTERONE; ANTIPYRINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; ISOENZYMES; KIDNEY; KINETICS; METABOLIC CLEARANCE RATE; MICROSOMES; MICROSOMES, LIVER; MOLECULAR STRUCTURE; NALOXONE; PROPOFOL; TANDEM MASS SPECTROMETRY;

BOVINAE;

EID: 84863376165     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.043356     Document Type: Article

References (36)

1. Baldelli S, Merlini S, Perico N, Nicastri A, Cortinovis M, Gotti E, Remuzzi G, and Cattaneo D (2007) C-440T/T-331C polymorphisms in the UGT1A9 gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics 8:1127-1141. (Pubitemid 47578222)
2. Bowalgaha K, Elliot DJ, Mackenzie PI, Knights KM, Swedmark S, and Miners JO (2005) S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol 60:423-433. (Pubitemid 41428474)
3. Bowalgaha K and Miners JO (2001) The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52:605-609.
4. Court MH, Krishnaswamy S, Hao Q, Duan SX, Patten CJ, Von Moltke LL, and Greenblatt DJ (2003) Evaluation of 3′-azido-3′-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31:1125-1133. (Pubitemid 37048284)
5. Di Marco A, D'Antoni M, Attaccalite S, Carotenuto P, and Laufer R (2005) Determination of drug glucuronidation and UDP-glucuronosyltransferase selectivity using a 96-well radiometric assay. Drug Metab Dispos 33:812-819. (Pubitemid 40686635)
6. Emi Y, Ikushiro S, and Iyanagi T (1995) Drug-responsive and tissue-specific alternative expression of multiple first exons in rat UDP-glucuronosyltransferase family 1 (UGT1) gene complex. J Biochem 117:392-399.
7. Hiraoka H, Yamamoto K, Miyoshi S, Morita T, Nakamura K, Kadoi Y, Kunimoto F, and Horiuchi R (2005) Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. Br J Clin Pharmacol 60:176-182. (Pubitemid 41075903)
8. Hishida A (2007) Clinical analysis of 207 patients who developed renal disorders during or after treatment with edaravone reported during post-marketing surveillance. Clin Exp Nephrol 11:292-296.
9. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362. (Pubitemid 34263817)
10. Iwuchukwu OF and Nagar S (2008) Resveratrol (trans-resveratrol, 3,5,4′-trihydroxy-transstilbene) glucuronidation exhibits atypical enzyme kinetics in various protein sources. Drug Metab Dispos 36:322-330. (Pubitemid 351185744)
11. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
12. Knights KM and Miners JO (2010) Renal UDP-glucuronosyltransferases and the glucuronidation of xenobiotics and endogenous mediators. Drug Metab Rev 42:63-73.
13. Komatsu T, Nakai H, Takamatsu Y, Morinaka Y, Watanabe K, Shinoda M, and Iida S (1996) Pharmacokinetic studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186): metabolism in rats, dogs and human. Drug Metab Pharmacokinet 11:451-462.
14. Krishnaswamy S, Duan SX, Von Moltke LL, Greenblatt DJ, Sudmeier JL, Bachovchin WW, and Court MH (2003) Serotonin (5-hydroxytryptamine) glucuronidation in vitro: assay development, human liver microsome activities and species differences. Xenobiotica 33:169-180. (Pubitemid 36237939)
15. Kuypers DR, Naesens M, Vermeire S, and Vanrenterghem Y (2005) The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients. Clin Pharmacol Ther 78:351-361. (Pubitemid 41393670)
16. Lapchak PA (2010) A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy? Expert Opin Pharmacother 11:1753-1763.
17. McGurk KA, Brierley CH, and Burchell B (1998) Drug glucuronidation by human renal UDP-glucuronosyltransferases. Biochem Pharmacol 55:1005-1012. (Pubitemid 28167722)
18. Ohno S and Nakajin S (2009) Determination of mRNA expression of human UDP-glucuronosyltransferases and application for localization in various human tissues by real-time reverse transcriptase-polymerase chain reaction. Drug Metab Dispos 37:32-40.
19. Ouzzine M, Barré L, Netter P, Magdalou J, and Fournel-Gigleux S (2003) The human UDP-glucuronosyltransferases: structural aspects and drug glucuronidation. Drug Metab Rev 35:287-303. (Pubitemid 38018108)
20. Picard N, Ratanasavanh D, Prémaud A, Le Meur Y, and Marquet P (2005) Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos 33:139-146. (Pubitemid 40023525)
21. Rowland A, Gaganis P, Elliot DJ, Mackenzie PI, Knights KM, and Miners JO (2007) Binding of inhibitory fatty acids is responsible for the enhancement of UDP-glucuronosyltransferase 2B7 activity by albumin: implications for in vitro-in vivo extrapolation. J Pharmacol Exp Ther 321:137-147. (Pubitemid 46456976)
22. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062. (Pubitemid 351717462)
23. Sánchez-Fructuoso AI, Maestro ML, Calvo N, Viudarreta M, Pérez-Flores I, Veganzone S, De la Orden V, Ortega D, Arroyo M, and Barrientos A (2009) The prevalence of uridine diphosphate- glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T and its influence on mycophenolic acid pharmacokinetics in stable renal transplant patients. Transplant Proc 41:2313-2316.
24. Shelby MK, Cherrington NJ, Vansell NR, and Klaassen CD (2003) Tissue mRNA expression of the rat UDP-glucuronosyltransferase gene family. Drug Metab Dispos 31:326-333. (Pubitemid 36249688)
25. Shibata H, Arai S, Izawa M, Murasaki M, Takamatsu Y, Izawa O, Takahashi C, and Tanaka M (1998) Phase I clinical study of MCI-186 (edaravone, 3-methyl-1-phenyl-2-pyrazolin-5-one) in healthy volunteers: safety and pharmacokinetics of single and multiple administrations. Jpn J Clin Pharmacol Ther 29:863-876. (Pubitemid 37070093)
26. Shiratani H, Katoh M, Nakajima M, and Yokoi T (2008) Species differences in UDP-glucuronosyltransferase activities in mice and rats. Drug Metab Dispos 36:1745-1752.
27. Soars MG, Riley RJ, Findlay KA, Coffey MJ, and Burchell B (2001) Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Dispos 29:121-126. (Pubitemid 32112924)
28. Sten T, Kurkela M, Kuuranne T, Leinonen A, and Finel M (2009) UDP-glucuronosyltransferases in conjugation of 5alpha- and 5beta-androstane steroids. Drug Metab Dispos 37:2221-2227.
29. Strassburg CP, Nguyen N, Manns MP, and Tukey RH (1999) UDP-glucuronosyltransferase activity in human liver and colon. Gastroenterology 116:149-160. (Pubitemid 29013504)
30. Takahashi R (2009) Edaravone in ALS. Exp Neurol 217:235-236.
31. Tsoutsikos P, Miners JO, Stapleton A, Thomas A, Sallustio BC, and Knights KM (2004) Evidence that unsaturated fatty acids are potent inhibitors of renal UDP-glucuronosyltransferases (UGT): kinetic studies using human kidney cortical microsomes and recombinant UGT1A9 and UGT2B7. Biochem Pharmacol 67:191-199. (Pubitemid 37518547)
32. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616. (Pubitemid 30340694)
33. Watanabe T, Tahara M, and Todo S (2008) The novel antioxidant edaravone: from bench to bedside. Cardiovasc Ther 26:101-114. (Pubitemid 351952827)
34. Watanabe Y, Nakajima M, Ohashi N, Kume T, and Yokoi T (2003) Glucuronidation of etoposide in human liver microsomes is specifically catalyzed by UDP-glucuronosyltransferase 1A1. Drug Metab Dispos 31:589-595. (Pubitemid 36444168)
35. Yokota S, Kumagai Y, Uchiumi M, Isawa S, Murasaki M, Akimoto K, Iwamoto M, Yuasa T, and Iwano M (1997) A pharmacokinetic study of MCI-186, a novel drug for cerebrovascular disease in elderly and young healthy subjects. Jpn J Clin Pharmacol Ther 28:693-702.
36. Zhu XR, Zheng Y, Wang P, Yang SB, Chen R, and Zhu YQ (2010) Synthesis of two metabolites of edaravone. J Chin Pharm Sci 19:307-311.